2. Search Result
Search Result
Results for "

DX 8951

" in MedChemExpress (MCE) Product Catalog:

50

Inhibitors & Agonists

2

Fluorescent Dye

2

Biochemical Assay Reagents

7

Isotope-Labeled Compounds

2

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13631
    Exatecan
    20+ Cited Publications

    DX-8951

    		 ADC Payload Topoisomerase Cancer
    Exatecan (DX-8951) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research.
    Exatecan
  • HY-13631E
    Deruxtecan
    Maximum Cited Publications
    25 Publications Verification

    MC-GGFG-DXD

    		 Drug-Linker Conjugates for ADC Cancer
    Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
    Deruxtecan
  • HY-13631A
    Exatecan mesylate
    20+ Cited Publications

    DX8951f

    		 ADC Payload Topoisomerase Cancer
    Exatecan mesylate (DX8951f) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL). Exatecan mesylate can be used in cancer research.
    Exatecan mesylate
  • HY-13631AS
    Exatecan-d5 mesylate

    DX8951f-d5; Deuterated labeled Exatecan mesylate

    		 Isotope-Labeled Compounds ADC Payload Topoisomerase Cancer
    Exatecan-d5 (DX8951f-d5) mesylate is deuterium labeled Exatecan mesylate (HY-13631A). Exatecan mesylate is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL). Exatecan mesylate can be used in cancer research .
    Exatecan-d5 mesylate
  • HY-114233
    MC-GGFG-Exatecan
    5+ Cited Publications

    MC-GGFG-DX8951

    		 Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC) .
    MC-GGFG-Exatecan
  • HY-13631R
    Exatecan (Standard)

    DX-8951 (Standard)

    		 ADC Payload Reference Standards Topoisomerase Cancer
    Exatecan (Standard) is the analytical standard of Exatecan. This product is intended for research and analytical applications. Exatecan (DX-8951) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research.
    Exatecan (Standard)
  • HY-145929
    MC-Val-Cit-PAB-Exatecan
    1 Publications Verification

    MC-Val-Cit-PAB-DX8951

    		 Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. MC-Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker.
    MC-Val-Cit-PAB-Exatecan
  • HY-153031
    Val-Cit-PAB-Exatecan

    Val-Cit-PAB-DX8951

    		 Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker .
    Val-Cit-PAB-Exatecan
  • HY-13631AG
    Exatecan mesylate

    DX8951f

    		 ADC Payload Topoisomerase Cancer
    Exatecan mesylate (DX8951f ) GMP is a GMP-class Exatecan (HY-13631). Exatecan is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research .
    Exatecan mesylate
  • HY-128995AS
    Glycyl-Exatecan-d5 hydrochloride

    Glycyl-DX-8951-d5 hydrochloride; Exatecan analog 2-d5 hydrochloride

    		 Isotope-Labeled Compounds ADC Payload Topoisomerase Cancer
    Glycyl-Exatecan-d5 (Glycyl-DX-8951-d5) hydrochloride is deuterium labeled Glycyl-Exatecan (HY-128995A). Glycyl-Exatecan (Glycyl-DX-8951), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan has significantly antitumor activity. Glycyl-Exatecan can be used for cancers like solid tumors research.
    Glycyl-Exatecan-d5 hydrochloride
  • HY-13631ES4
    Deruxtecan-d5

    MC-GGFG-DXD-d5

    		 Isotope-Labeled Compounds Drug-Linker Conjugates for ADC Cancer
    Deruxtecan-d5 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d5
  • HY-44369
    Exatecan Intermediate 6

    		ADC Payload Topoisomerase Cancer
    Exatecan Intermediate 6 is the intermediate of Exatecan (HY-13631) And Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL) that can be used in cancer research. Exatecan Intermediate 6 can be used to synthesize Antibody-Drug Conjugates (ADCs).
    Exatecan Intermediate 6
  • HY-W021377
    Exatecan Intermediate 2

    		ADC Payload Drug Intermediate Cancer
    Exatecan Intermediate 2 (Compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .
    Exatecan Intermediate 2
  • HY-13631EG
    Deruxtecan

    MC-GGFG-DXD

    		 Drug-Linker Conjugates for ADC Cancer
    Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
    Deruxtecan
  • HY-13631J
    (1R,9R)-Exatecan mesylate

    (1R,9R)-DX8951f

    		 Drug Derivative Topoisomerase Apoptosis Cancer
    (1R,9R)-Exatecan mesylate ((1R,9R)-DX8951f) is a non-prodrug camptothecin derivative and a potent topoisomerase I inhibitor (IC50=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1R,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1R,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1R,9R)-Exatecan mesylate is widely used in preclinical studies of multiple cancers including pancreatic cancer, lung cancer, breast cancer, and leukemia . The low-activity isomer of (1R,9R)-Exatecan mesylate is (1S,9R)-Exatecan mesylate (HY-13631I).
    (1R,9R)-Exatecan mesylate
  • HY-13631I
    (1S,9R)-Exatecan mesylate

    (1S,9R)-DX8951f

    		 Drug Derivative Topoisomerase Apoptosis Cancer
    (1S,9R)-Exatecan mesylate ((1S,9R)-DX8951f) is a non-prodrug camptothecin derivative and a topoisomerase I inhibitor (IC50=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1S,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1S,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1S,9R)-Exatecan mesylate is widely used in preclinical studies of various cancers such as pancreatic cancer, lung cancer, breast cancer, and leukemia .
    The chiral isomer of (1S,9R)-Exatecan mesylate is (1R,9R)-Exatecan mesylate (HY-13631J).
    (1S,9R)-Exatecan mesylate
  • HY-42487B
    (R)-Exatecan Intermediate 1

    		Drug Intermediate ADC Payload Topoisomerase Cancer
    (R)-Exatecan Intermediate 1 is a key intermediate in the synthesis of Camptothecin (HY-16560) derivatives, and can be used to prepare Exatecan mesylate (DX8951f) (HY-13631A). (R)-Exatecan Intermediate 1 enables the synthesis of Exatecan, which exhibits low sensitivity to multidrug resistance and has great value in anti-tumor research .
    (R)-Exatecan Intermediate 1
  • HY-43565
    Exatecan intermediate 9

    		ADC Payload Topoisomerase Cancer
    Exatecan intermediate 9 is an intermediate for the synthesis of Exatecan (HY-13631). Exatecan (DX-8951) is a common toxin component in ADC preparation (ADC Cytotoxin) and an inhibitor of DNA topoisomerase I (IC50=2.2 μM) .
    Exatecan intermediate 9
  • HY-178239
    DX-8951 Hydroxy-acid

    		Drug Metabolite AMPK Reactive Oxygen Species (ROS) Inflammation/Immunology
    DX-8951 Hydroxy-acid is a prodrug of phosphoramide. ProAX can effectively increase intracellular ATP levels. DX-8951 Hydroxy-acid activates the AMPK signaling pathway by increasing the AMP/ATP ratio. DX-8951 Hydroxy-acid can enhance mitochondrial function and antioxidant capacity while reducing reactive oxygen species (ROS) levels. DX-8951 Hydroxy-acid has shown significant anti-aging and longevity effects in both human fibroblast and nematode models .
    DX-8951 Hydroxy-acid
  • HY-128995A
    Glycyl-Exatecan TFA

    Glycyl-DX-8951 TFA; Exatecan analog 2 TFA

    		 Drug Derivative Cancer
    Glycyl-Exatecan TFA (Glycyl-DX-8951 TFA), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan TFA has significantly antitumor activity. Glycyl-Exatecan TFA can be used for cancers like solid tumors research .
    Glycyl-Exatecan TFA
  • HY-13631P
    Exatecan mesylate dihydrate

    DX-8951 mesylate dihydrate

    		 ADC Payload Topoisomerase Cancer
    Exatecan (DX-8951) mesylate dihydrate is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research .
    Exatecan mesylate dihydrate
  • HY-153031A
    Val-Cit-PAB-Exatecan TFA

    Val-Cit-PAB-DX8951 TFA

    		 Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) TFA is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan TFA is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker .
    Val-Cit-PAB-Exatecan TFA
  • HY-178239A
    DX-8951 Hydroxy-acid sodium

    		Drug Metabolite AMPK Reactive Oxygen Species (ROS) Inflammation/Immunology
    DX-8951 Hydroxy-acid sodium is a prodrug of phosphoramide. DX-8951 Hydroxy-acid sodium can effectively increase intracellular ATP levels. DX-8951 Hydroxy-acid sodium activates the AMPK signaling pathway by increasing the AMP/ATP ratio. DX-8951 Hydroxy-acid sodium can enhance mitochondrial function and antioxidant capacity while reducing reactive oxygen species (ROS) levels. DX-8951 Hydroxy-acid sodium has shown significant anti-aging and longevity effects in both human fibroblast and nematode models .
    DX-8951 Hydroxy-acid sodium
  • HY-13631ES3
    Deruxtecan-d2

    MC-GGFG-DXD-d2

    		 Drug-Linker Conjugates for ADC Isotope-Labeled Compounds Others
    Deruxtecan-d2 is the deuterium labeled Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d2
  • HY-W021377B
    Exatecan Intermediate 4

    		ADC Payload Drug Intermediate Cancer
    Exatecan Intermediate 4 (Compound 14f) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .
    Exatecan Intermediate 4
  • HY-160755
    UM-2

    		Endogenous Metabolite Others
    UM-2 is the urinary 3-hydroxy metabolite of DX-8951 (HY-13631) in human .
    UM-2
  • HY-13631ES
    Deruxtecan-d4

    MC-GGFG-DXD-d4

    		 Drug-Linker Conjugates for ADC Isotope-Labeled Compounds Others
    Deruxtecan-d4 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d4
  • HY-W021377A
    Exatecan Intermediate 2 hydrochloride

    		ADC Payload Drug Intermediate Cancer
    Exatecan Intermediate 2 hydrochloride (Compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .
    Exatecan Intermediate 2 hydrochloride
  • HY-13631T
    (1R,9S)-Exatecan

    (1R,9S)-DX8951f

    		 Drug Derivative ADC Payload Topoisomerase Cancer
    (1R,9S)-Exatecan (DX8951f) is the (1R,9S) stereoisomer of Exatecan (HY-13631). Exatecan (DX-8951) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research .
    (1R,9S)-Exatecan
  • HY-174277
    Antitumor agent-203

    		ADC Payload Topoisomerase Cancer
    Antitumor agent-203 (例7) is a derivative of Exatecan (DX-8951) (HY-13631) and can be used to prepare antibody-drug conjugates (ADCs), as the ADC Cytotoxin .
    Antitumor agent-203
  • HY-13631N
    (9R)-Exatecan

    (9R)-DX8951f

    		 Drug Derivative ADC Payload Topoisomerase Cancer
    (9R)-Exatecan (DX8951f) is the (1R,9S) stereoisomer of Exatecan (HY-13631). Exatecan (DX-8951) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research.
    (9R)-Exatecan
  • HY-43564
    Exatecan Intermediate 5

    		ADC Payload Topoisomerase Cancer
    Exatecan Intermediate 5 is the intermediate of Exatecan (HY-13631) And Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL) that can be used in cancer research. Exatecan Intermediate 5 can be used to synthesize Antibody-Drug Conjugates (ADCs).
    Exatecan Intermediate 5
  • HY-45157
    Exatecan Intermediate 7

    		ADC Payload Topoisomerase Cancer
    Exatecan Intermediate 7 is the intermediate of Exatecan (HY-13631) And Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL) that can be used in cancer research. Exatecan Intermediate 7 can be used to synthesize Antibody-Drug Conjugates (ADCs).
    Exatecan Intermediate 7
  • HY-13631ES2
    Deruxtecan-d4-1

    MC-GGFG-DXD-d4-1

    		 Drug-Linker Conjugates for ADC Isotope-Labeled Compounds Others
    Deruxtecan-d4-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E) . Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d4-1
  • HY-178257
    Fmoc-Val-Lys-PAB-Exatecan

    		ADC Payload Cancer
    Fmoc-Val-Lys-PAB-Exatecan is a derivative of Exatecan (DX-8951) (HY-13631). Fmoc-Val-Lys-PAB-Exatecan can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. Fmoc-Val-Lys-PAB-Exatecan is often combined with CD70 mAb to form ADC drugs for the study of tumors with high CD70 expression .
    Fmoc-Val-Lys-PAB-Exatecan
  • HY-13631U
    Exatecan hydrochloride

    DX-8951 hydrochloride

    		 ADC Payload Topoisomerase Cancer
    Exatecan (DX-8951) hydrochloride is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research .
    Exatecan hydrochloride
  • HY-13631AS1
    Exatecan-d3 mesylate

    DX8951f-d3 mesylate

    		 Topoisomerase Isotope-Labeled Compounds ADC Payload Cancer
    Exatecan-d3 (DX8951f-d3) mesylate is deuterium-labeled Exatecan mesylate (HY-13631A). Exatecan mesylate is a DNA topoisomerase I inhibitor, with an IC50 of 0.975 μg/mL .
    Exatecan-d3 mesylate
  • HY-153236
    Py-MAA-Val-Cit-PAB-DX8951

    		Nucleoside Antimetabolite/Analog Others
    Py-MAA-Val-Cit-PAB-DX8951 is a purine toxin. Py-MAA-Val-Cit-PAB-DX8951 can be used as an intermediate in the synthesis of antibody-drug conjugates .
    Py-MAA-Val-Cit-PAB-DX8951
  • HY-128979B
    Deruxtecan analog 2 monoTFA

    		Drug-Linker Conjugates for ADC Cancer
    Deruxtecan analog 2 (monoTFA) is a homolog of Deruxtecan (HY-13631E), a conjugate of the ADC toxin DX-8951 derivative (Dxd) with an ADC Linker .
    Deruxtecan analog 2 monoTFA
  • HY-48878
    Exatecan analog 36

    		ADC Payload Topoisomerase Cancer
    Exatecan analog 36 is a analog of Exatecan (HY-13631). Exatecan (DX-8951) is a common toxin component in ADC preparation (ADC Cytotoxin) and an inhibitor of DNA topoisomerase I (IC50=2.2 μM) .
    Exatecan analog 36
  • HY-46081
    Exatecan Intermediate 3

    		ADC Payload Topoisomerase Cancer
    Exatecan Intermediate 3 is the intermediate of Exatecan (HY-13631) And Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL) that can be used in cancer research. Exatecan Intermediate 3 can be used to synthesize Antibody-Drug Conjugates (ADCs).
    Exatecan Intermediate 3
  • HY-43565B
    Exatecan intermediate 10

    		ADC Payload Topoisomerase Cancer
    Exatecan intermediate 10 is an intermediate in the synthesis of Exatecan (HY-13631).Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 of 2 .2 μM (0 .975 μg/mL) for use in cancer research .
    Exatecan intermediate 10
  • HY-49861
    Exatecan intermediate 11

    		ADC Payload Topoisomerase Cancer
    Exatecan intermediate 11 is an intermediate for the synthesis of Exatecan (HY-13631). Exatecan (DX-8951) is a common toxin component in ADC preparation (ADC Cytotoxin) and an inhibitor of DNA topoisomerase I (IC50=2.2 μM) .
    Exatecan intermediate 11
  • HY-400316
    Exatecan intermediate 8

    		ADC Payload Topoisomerase Cancer
    Exatecan intermediate 8 is an intermediate for the synthesis of Exatecan (HY-13631). Exatecan (DX-8951) is a common toxin component in ADC preparation (ADC Cytotoxin) and an inhibitor of DNA topoisomerase I (IC50=2.2 μM) .
    Exatecan intermediate 8
  • HY-157795
    Exatecan analogue 1

    		ADC Payload Topoisomerase Cancer
    Exatecan analogue 1 (Icp-3) is a Exatecan (HY-13631) analogue. Exatecan analogue 1 can be used in the synthesis of antibody-drug conjugates (ADCs)
    Exatecan analogue 1
  • HY-W021377C
    Exatecan Intermediate 4 dihydrochloride

    		ADC Payload Drug Intermediate Cancer
    Exatecan Intermediate 4 dihydrochloride (Compound 14f) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .
    Exatecan Intermediate 4 dihydrochloride
  • HY-13631G
    Exatecan analog 13

    		ADC Payload Topoisomerase Cancer
    Exatecan analog 13 is a analog of Exatecan (HY-13631). Exatecan (DX-8951) is a common toxin component in ADC preparation (ADC Cytotoxin) and an inhibitor of DNA topoisomerase I (IC50 = 2.2 μM) .
    Exatecan analog 13
  • HY-128995
    Glycyl-Exatecan

    Glycyl-DX-8951; Exatecan analog 2

    		 Drug Metabolite Cancer
    Glycyl-Exatecan (Glycyl-DX-8951) is an active metabolite released from DE-310 by enzymatic cleavage of the spacer. Glycyl-Exatecan exerts anti-tumor activity in vivo. Glycyl-Exatecan can be used for solid tumor research .
    Glycyl-Exatecan
  • HY-185101
    MC-AcLys-GDEVD-PABC-Exatecan

    		Drug-Linker Conjugates for ADC Cancer
    MC-AcLys-GDEVD-PABC-Exatecan (MC-AcLys-GDEVD-PABC-DX8951) is a agent-linker conjugate for ADC. MC-AcLys-GDEVD-PABC-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with a novel caspase-3 cleavable peptide linker MC-AcLys-GDEVD-PABC linker. MC-AcLys-GDEVD-PABC-Exatecan can be used to prepare DX8951 antibody conjugate (ADC), and it exhibites significant bystander effect mediated by the caspase-3-triggered extracellular cleavage of the linker, enhancing payload release into the tumor microenvironment.
    MC-AcLys-GDEVD-PABC-Exatecan
  • HY-43565C
    (1S,9R)-Ac-Exatecan

    		Drug Intermediate Cancer
    (1S,9R)-Ac-Exatecan is an intermediate for the synthesis of Exatecan (HY-13631). Exatecan (DX-8951) is a common toxin component in ADC preparation (ADC Cytotoxin) and an inhibitor of DNA topoisomerase I (IC50=2.2 μM) .
    (1S,9R)-Ac-Exatecan

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: